Newsfile (Mon, 18-May 7:00 AM ET)
BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
Newsfile (Thu, 14-May 7:00 AM ET)
BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division
Newsfile (Wed, 13-May 5:33 PM ET)
Newsfile (Wed, 13-May 8:01 AM ET)
Newsfile (Tue, 12-May 7:30 AM ET)
BioHarvest Sciences to Report First Quarter 2026 Financial Results on May 14, 2026
Newsfile (Thu, 30-Apr 4:05 PM ET)
Newsfile (Wed, 29-Apr 8:30 AM ET)
BioHarvest Sciences Reports Fourth Quarter and Full-Year 2025 Financial Results
Newsfile (Tue, 31-Mar 4:02 PM ET)
Newsfile (Tue, 31-Mar 8:00 AM ET)
Newsfile (Thu, 26-Mar 7:30 AM ET)
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
Bioharvest Sciences trades on the NASDAQ stock market under the symbol BHST.
As of June 15, 2026, BHST stock price climbed to $3.27 with 296 million shares trading.
BHST has a beta of 1.09, meaning it tends to be more sensitive to market movements. BHST has a correlation of 0.03 to the broad based SPY ETF.
BHST has a market cap of $74.08 million. This is considered a Micro Cap stock.
Last quarter Bioharvest Sciences reported $9 million in Revenue and -$.11 earnings per share. This fell short of revenue expectation by $-296,000 and exceeded earnings estimates by $.01.
BHST has underperformed the market in the last year with a price return of -57.3% while the SPY ETF gained +26.0%. BHST has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.6% and -15.3%, respectively, while the SPY returned +13.3% and -0.4%, respectively.
BHST support price is $3.04 and resistance is $3.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHST shares will trade within this expected range on the day.
